

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



奧園健康生活集團有限公司
AOYUAN HEALTHY LIFE GROUP COMPANY LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3662)

**RESUMPTION GUIDANCE
AND UPDATE INFORMATION**

This announcement is made by Aoyuan Healthy Life Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (a) the inside information announcement of the Company dated 30 March 2022 in relation to, among others, the delay in the publication of the annual results of the Group for the financial year ended 31 December 2021 (the “**2021 Annual Results**”) and the despatch of the Company’s annual report for the financial year ended 31 December 2021 (the “**2021 Annual Report**”); (b) the inside information announcement of the Company dated 3 May 2022 in relation to, among others, certain fund flows matters, the formation of the independent investigation committee of the Company and the appointment of independent professional advisers; and (c) the inside information announcement of the Company dated 2 June 2022 in relation to, among others, the change of auditor of the Company and certain allegations against the Group (the “**Announcements**”). Unless otherwise stated, terms used in this announcement shall have the same respective meanings as those defined in the Announcements.

RESUMPTION GUIDANCE

On 27 June 2022, the Company received the following resumption guidance (the “**Resumption Guidance**”) from the Stock Exchange:

- (a) publish all outstanding financial results required under the Listing Rules and address any audit modifications;
- (b) conduct an appropriate independent forensic investigation into the Fund Flows Matters and the Allegations, announce the findings and take appropriate remedial actions;

- (c) conduct an independent internal control review and demonstrate that the Company has in place adequate internal controls and procedures to meet the obligations under the Listing Rules;
- (d) demonstrate that there is no reasonable regulatory concern about management integrity and/or the integrity of any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence;
- (e) demonstrate that the Directors meet a standard of competence commensurate with their positions as directors of a listed issuer to fulfill duties of skill, care and diligence as required under Rules 3.08 and 3.09 of the Listing Rules;
- (f) demonstrate the Company's compliance with Rule 13.24 of the Listing Rules; and
- (g) inform the market of all material information for the Shareholders and investors of the Company to appraise the Company's position.

The Stock Exchange also states that the Company must meet all Resumption Guidance, remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange's satisfaction before trading in its securities is allowed to resume. For this purpose, the Company has the primary responsibility to devise its action plan for resumption. Whilst the Company may seek the Stock Exchange's guidance on its resumption plan, its resumption plan is not subject to the prior approval from the Stock Exchange before implementation. The Stock Exchange further indicates that it may modify or supplement the Resumption Guidance if the Company's situation changes.

Under Rule 6.01A(1) of the Listing Rules, the Stock Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 18 months. In the case of the Company, the 18-month period expires on 30 September 2023. If the Company fails to remedy the issues causing its trading suspension, fulfill the Resumption Guidance and fully comply with the Listing Rules to the Stock Exchange's satisfaction and resume trading in its shares by 30 September 2023, the Listing Division will recommend the Listing Committee to proceed with the cancellation of the Company's listing. Under Rules 6.01 and 6.10 of the Listing Rules, the Stock Exchange also has the right to impose a shorter specific remedial period, where appropriate.

UPDATE INFORMATION

Business operations

The Group is principally engaged in the provision of the property management services and commercial operational services for properties developed or owned by the property developers in the People's Republic of China. Meanwhile, the Group is deepening and expanding diversified health and wellness services, developing mature community healthcare, and other businesses. Notwithstanding the suspension of trading in the shares of the Company, the Group is carrying on its business operations as usual and will continue to closely monitor its financial position and business operations.

Independent investigations of the Fund Flows Matters and the Allegations

The Company has actively cooperated with the Investigation Firm in relation to the independent investigations of the Fund Flows Matters and the Allegations and as at the date of this announcement, the progress of such investigations has been smooth and positive. Further to the independent investigations, the Investigation Firm will also suggest measures to improve the internal control system of the Group. As the Investigation Firm is still conducting the investigations and the independent legal adviser is still working on the legal opinion, the expected timing for the completion of the independent investigations is yet to be determined at this stage.

2021 Annual Results

The Company has been working closely with its auditor on the audit work of the 2021 Annual Results. Subject to the ongoing independent investigations of the Fund Flows Matters and the Allegations, the Company is yet to determine the estimated timing for the publication of the 2021 Annual Results.

The Company will announce updated information on the above matters in due course.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Friday, 1 April 2022 and will continue to be suspended, pending the publication of the 2021 Annual Results.

The Company is taking appropriate steps to comply with the Resumption Guidance and the relevant Listing Rules and will announce quarterly updates on its development of the resumption status pursuant to Rule 13.24A of the Listing Rules.

By order of the Board
Aoyuan Healthy Life Group Company Limited
Guo Zining
Chairman

Hong Kong, 30 June 2022

As at the date of this announcement, the executive Directors are Mr. Zheng Wei and Mr. Cheng Siu Fai; the non-executive Directors are Mr. Guo Zining and Mr. Ruan Yongxi; and the independent non-executive Directors are Mr. Hung Ka Hai Clement, Dr. Li Zijun and Mr. Wang Shao.